🌎 Worldwide

No Result

View All Result

No Result

View All Result

No Result

View All Result

Home United States Connecticut

Connecticut Expands its List of Medical Marijuana Qualifying Conditions

by Susie Peterson

November 12, 2018

in Connecticut, Doctors, Patients, United States, Video

Photo by rawpixel.com on Pexels.com

71

SHARES

Share Share

Connecticut lawmakers have now added chronic neuropathic pain associated with degenerative spinal disorders as a qualifying condition for medical marijuana, making it the 31st condition approved for treatment with medicinal cannabis.

Alongside this, the General Assembly’s Regulations Review Committee also agreed to update the Connecticut state laws to reflect the FDA’s recent approval of CBD-based EPIDIOLEX from GW Pharmaceuticals plc (NASDAQ:GWPH).

As of November 11th, Connecticut had 29,561 registered patients and 1,003 registered physicians in its medical marijuana program.

Be sure to subscribe to Connecticut Marijuana News Updates here so you never miss an important update!

Tags: chronic neuropathic pain Epidiolex medical marijuana

Get Real-Time Updates from MJobserver.com

Unsubscribe

Susie Peterson

Susie is a staff writer for MJobserver.com covering a wide variety of topics within the cannabis industry ranging from business to lifestyle.

Related Posts

Epidiolex from GW Pharmaceuticals

Investments

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 3, 2021

Thailand Cannabis News

Thailand

Thailand Marijuana Legalization as of 2020

Hexo Tsunami 30 gram medical cannabis

Canada

HEXO Launches New Tsunami 30 g Flower Format Exclusively to Medical Clients

London, U.K. Medicinal Cannabis News

United Kingdom

Althea Signs Medicinal Cannabis Supply Agreement with UK’s Grow Pharma

GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

Investments

GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

Investments

GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

Load More

Next Post

AgraFlora Premium Hemp Brands to List on Amazon and Other Online Retail Channels

Independent Report Highlights BioTrackTHC, a Helix TCS, Inc. Company, as Leading Provider of Dispensary Point-of-Sale Software in U.S. Cannabis Industry

Comments 1

Pingback: Weedmaps Launches Billboard in Connecticut Advertising Massachusetts Marijuana

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

Cannabis Tools & Resources

Find Cannabis Business Services

The Daily Marijuana Observer

Advertise with Us

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result

View All Result

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.